Investigating the effect of quince oxymel on non-alcoholic fatty liver

Investigating the therapiotic effect of quince oxymel on treatment of non-alcoholic fatty liver disease - Randomized clinical Trial, triple Blinded, placebo controlled

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221202056689N1

Enrollment

Registered

2023-01-25

Start date

2022-12-29

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention groupPatients with fatty liver referred to the gastroenterology clinic of Shahid Beheshti Hospital in Qom are selected according to the entry criteria and randomly divided

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients between the ages of 20 and 65 years are diagnosed with grade 2 or higher fatty liver based on the ultrasound report liver enzymes that are higher than the normal level.

Exclusion criteria

Exclusion criteria: Having diabetes Viral hepatitis and autoimmune hepatitis Having metabolic diseases such as Wilson's disease and hemochromatosis History of alcohol consumption and alcoholic beverages Liver transplant at some point in the past Taking any type of medicine to treat fatty liver in the past one month The patient's unwillingness to continue the plan Severe allergy or drug complication Pregnancy and breastfeeding Taking Varfarin, heparin compounds and anticoagulant drugs

Design outcomes

Primary

Measure	Time frame
Non-alcoholic fatty liver grade. Timepoint: At the beginning of the study (before the start of the intervention) and twelve weeks after the intervention. Method of measurement: ultrasound device.;Alanine aminotransferase enzyme. Timepoint: ?? ?????? ?????? ( ??? ?? ???? ?????? ) ? ?????? ???? ??? ?? ??????. Method of measurement: Measuring the serum level of alanine aminotransferase enzyme in peripheral blood samples.;Aspartate aminotransferase. Timepoint: ?? ?????? ?????? ( ??? ?? ???? ?????? ) ? ?????? ???? ??? ?? ??????. Method of measurement: ?????? ???? ??? ???? ????? ???????? ????? ????????? ?? ????? ??? ?????.	—

Measure

Time frame

Non-alcoholic fatty liver grade. Timepoint: At the beginning of the study (before the start of the intervention) and twelve weeks after the intervention. Method of measurement: ultrasound device.;Alanine aminotransferase enzyme. Timepoint: ?? ?????? ?????? ( ??? ?? ???? ?????? ) ? ?????? ???? ??? ?? ??????. Method of measurement: Measuring the serum level of alanine aminotransferase enzyme in peripheral blood samples.;Aspartate aminotransferase. Timepoint: ?? ?????? ?????? ( ??? ?? ???? ?????? ) ? ?????? ???? ??? ?? ??????. Method of measurement: ?????? ???? ??? ???? ????? ???????? ????? ????????? ?? ????? ??? ?????.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrdad Ababaf Shoushtari(

Ghoum University of Medical Sciences

mehrdadbabaf@yahoo.com+98 25 3776 4073

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026